Release of Indian Pharmacopoeia (IP)-2018
With a view to strengthen the quality of drugs in India, Shri C.K. Mishra, Secretary, Ministry of Health & Family Welfare, Govt. of India, released the Eighth Edition of Indian Pharmacopoeia, IP-2018 on 29th September, 2017 at Nirman Bhawan, New Delhi.
Secretary, Ministry of Health & Family Welfare Shri C.K. Mishra, releasing the Indian Pharmacopoeia 2018 in the presence of Dr. R.K. Vats, Additional Secretary & DG (CGHS) MoFHW, Dr. Jagdish Prasad, DG, DGHS, MoHFW, Dr. G. N. Singh, Secretary-cum-Scientific Director, IPC and various other dignitaries
Shri C.K. Mishra, Secretary, MoHFW congratulated Indian Pharmacopoeia Commission (IPC) and the expert members of the Scientific Body, IPC staff and various other professionals and organizations for this achievement. He said that to keep pace with the rapidly changing standards of drug all over world, it was necessary bringing the new edition of Indian Pharmacopoeia.
The Eighth edition of Indian Pharmacopoeia (IP- 2018) is published by the Indian Pharmacopoeia Commission (IPC) on behalf of the Ministry of Health & Family Welfare, Government of India in fulfilment of the requirements of the Drugs and Cosmetics Act, 1940 and the Rules there under.
On this occasion, Dr. G.N. Singh, Secretary-cum-Scientific Director, IPC highlighted various salient features of IP-2018 and said that with a view to meet the essential requirement for harmonization of analytical methods with those accepted internationally, steps have been taken for monitoring and upgrading drug standards in IP-2018. He said that publication of IP on regular basis is an important mandate of IPC and is aimed at improvement of health of the people through ensuring the quality, safety and efficacy of medicines. The standards given in this pharmacopoeia are authoritative, legally enforceable and intended to help in the licensing of manufacturing, inspection and distribution of medicines.
IP-2018 has been brought out in 4 Volumes incorporating 220 new monographs (Chemical Monographs (170), Herbal Monographs (15), Blood and Blood related products (10), Vaccines and Immunosera for Human use monographs (02), Radiopharmaceutical monographs (03), Biotechnology Derived Therapeutic Products (06), Veterinary monographs (14)), 366 revised monographs and 7 omissions. Standards for new drugs and drugs used under National Health Programmes are also included. 53 New Fixed Dose Combination (FDC’s) combination monographs have been included, out of which 25 FDC monographs are not available in any Pharmacopoeia.
It is hoped that this edition would play a significant role in improving the quality of medicines which in turn promote public health and accelerate the growth and development of Pharma Sector.